Recognition of highly degenerate mammalian splice sites by the core spliceosomal machinery is regulated by several protein factors that predominantly bind exonic splicing motifs. These are postulated to be single-stranded in order to be functional, yet knowledge of secondary structural features that regulate the exposure of exonic splicing motifs across the transcriptome is not currently available. Using transcriptome-wide RNA structural information we show that retained introns in mouse are commonly flanked by a short (≲70 nucleotide), highly base-paired segment upstream and a predominantly single-stranded exonic segment downstream. Splicing assays with select pre-mRNA substrates demonstrate that loops immediately upstream of the introns contain pre-mRNA-specific splicing enhancers, the substitution or hybridization of which impedes splicing. Additionally, the exonic segments flanking the retained introns appeared to be more enriched in a previously identified set of hexameric exonic splicing enhancer (ESE) sequences compared to their spliced counterparts, suggesting that base-pairing in the exonic segments upstream of retained introns could be a means for occlusion of ESEs. The upstream exonic loops of the test substrate promoted recruitment of splicing factors and consequent pre-mRNA structural remodeling, leading up to assembly of the early spliceosome. These results suggest that disruption of exonic stem–loop structures immediately upstream (but not downstream) of the introns regulate alternative splicing events, likely through modulating accessibility of splicing factors.

For splicing of a metazoan pre-mRNA, the four major splice signals -5′ and 3′ splice sites (SS), branch-point site (BS), and a poly-pyrimidine tract (PPT) -are initially bound by splicing factors U1 snRNP, U2AF35, SF1, and U2AF65, respectively, leading up to an early spliceosomal complex, the E-complex. The E-complex consists of additional components and the mechanism of its assembly is unclear. Hence, how splice signals are organized within E-complex defining the exon-intron boundaries remains elusive. Here we present in vitro stepwise reconstitution of an early spliceosome, assembled by cooperative actions of U1 snRNP, SRSF1, SF1, U2AF65, U2AF35, and hnRNP A1, termed here the recognition (R) complex, within which both splice sites are recognized. The R-complex assembly indicates that the SRSF1:pre-mRNA complex initially defines a substrate for U1 snRNP, engaging exons at both ends of an intron. Subsequent 5′SSdependent U1 snRNP binding enables recognition of the remaining splice signals, defining the intron. This R-complex assembly indicates the minimal constituents for intron definition revealing mechanistic principles behind the splice site recognition.

RNA splicing dysregulation underlies the onset and progression of cancers. In chronic lymphocytic leukemia (CLL), spliceosome mutations leading to aberrant splicing occur in ∼20% of patients. However, the mechanism for splicing defects in spliceosome-unmutated CLL cases remains elusive. Through an integrative transcriptomic and proteomic analysis, we discover that proteins involved in RNA splicing are posttranscriptionally upregulated in CLL cells, resulting in splicing dysregulation. The abundance of splicing complexes is an independent risk factor for poor prognosis. Moreover, increased splicing factor expression is highly correlated with the abundance of METTL3, an RNA methyltransferase that deposits N6-methyladenosine (m6A) on mRNA. METTL3 is essential for cell growth in vitro and in vivo and controls splicing factor protein expression in a methyltransferase-dependent manner through m6A modification-mediated ribosome recycling and decoding. Our results uncover METTL3-mediated m6A modification as a novel regulatory axis in driving splicing dysregulation and contributing to aggressive CLL. Significance: METTL3 controls widespread splicing factor abundance via translational control of m6A-modified mRNA, contributes to RNA splicing dysregulation and disease progression in CLL, and serves as a potential therapeutic target in aggressive CLL. See related commentary by Janin and Esteller.

No abstract